teplizumab (Tzield) Report issue

Biologics mAb Approved FDA First in Class Breakthrough Therapy FDA Priority Review FDA
AACT ChEMBL MeSH

Active Ingredient History

NOW
  • Now
Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Alternative names

anti-cd3 monoclonal antibody | hokt3gamma1 | hokt3 gamma 1 (ala-ala) | hokt3gamma1 (ala-ala) | hokt3gamma1(ala-ala) | hokt3γ1 | humanized okt3 gamma1(ala-ala) | humanized okt3gamma1(ala-ala) | humanzied okt3 | mga031 | okt3gamma1 ala-ala, humanized | teplizumab

Organizations (24)

Research & Development (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (1)


 

Diabetes Mellitus, Type 1 (approved 2022)

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Arthritis, Psoriatic (Phase 2)

Autoimmune Diseases (Phase 2)

Diabetes Mellitus, Experimental (Phase 1/Phase 2)

Diabetes Mellitus, Type 1 (Phase 4)

Glucose Intolerance (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hypoglycemia (Phase 1/Phase 2)

Islets of Langerhans Transplantation (Phase 1/Phase 2)

Maintenance (Phase 3)

Melanoma (Phase 1)

Nasopharyngeal Carcinoma (Phase 3)

Psoriasis (Phase 1/Phase 2)

Salivary Gland Neoplasms (Phase 1/Phase 2)

Transplantation, Homologous (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial Organizations: 24

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue